• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.乌克兰基辅州耐多药结核病治疗效果不佳的风险因素。
BMC Infect Dis. 2017 Feb 7;17(1):129. doi: 10.1186/s12879-017-2230-2.
2
Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.南非约翰内斯堡锡兹韦热带病医院接受抗逆转录病毒治疗的耐多药结核病合并人类免疫缺陷病毒感染患者的治疗结果
BMC Infect Dis. 2015 Oct 28;15:478. doi: 10.1186/s12879-015-1214-3.
3
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.儿童耐多药结核病的治疗和结局:系统评价和个体患者数据荟萃分析。
PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.
4
High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.2000-2003 年南非夸祖鲁-纳塔尔省耐多药结核病患者的高治疗失败率和高失访率。
Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9.
5
Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.南非约翰内斯堡锡兹韦热带病医院HIV合并感染的耐多药结核病患者的治愈预测因素。
Trans R Soc Trop Med Hyg. 2015 May;109(5):340-8. doi: 10.1093/trstmh/trv025. Epub 2015 Mar 18.
6
Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.耐多药结核病患者不良治疗结局的预测因素:一项回顾性队列研究。
Clin Microbiol Infect. 2018 Jun;24(6):612-617. doi: 10.1016/j.cmi.2017.09.012. Epub 2017 Sep 29.
7
Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.莱索托艾滋病毒合并感染患者早期开始抗逆转录病毒治疗对耐多药结核病治疗结局的影响。
PLoS One. 2012;7(10):e46943. doi: 10.1371/journal.pone.0046943. Epub 2012 Oct 24.
8
Patient predictors of poor drug sensitive tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.乌克兰基辅州药物敏感性肺结核治疗效果不佳的患者预测因素
F1000Res. 2017 Oct 23;6:1873. doi: 10.12688/f1000research.12687.3. eCollection 2017.
9
Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.与塞拉利昂耐多药结核病患者不良治疗结局相关的因素:一项横断面二次数据分析。
BMC Infect Dis. 2024 Jun 11;24(1):579. doi: 10.1186/s12879-024-09370-5.
10
Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa.南非图盖拉弗利的 HIV 合并耐多药结核病患者的文化转变。
PLoS One. 2011 Jan 6;6(1):e15841. doi: 10.1371/journal.pone.0015841.

引用本文的文献

1
Risk factors for poor outcomes in patients with drug-resistant tuberculosis: a 6-year multicenter prospective study in Zhejiang, China.耐多药结核病患者不良结局的危险因素:中国浙江一项为期6年的多中心前瞻性研究
BMC Infect Dis. 2025 Mar 27;25(1):422. doi: 10.1186/s12879-025-10802-z.
2
Perspectives on multisectoral accountability framework to end tuberculosis in the Eastern Europe and Central Asia region: a mixed-methods study.东欧和中亚地区终结结核病的多部门问责框架视角:一项混合方法研究
BMC Glob Public Health. 2025 Mar 5;3(1):20. doi: 10.1186/s44263-025-00136-y.
3
Applying a Combined Model to Evaluate the Risk of Poor Treatment Outcomes in Rifampicin Resistant Tuberculosis Patients: A Multicenter Retrospective Study.应用联合模型评估耐利福平结核病患者治疗效果不佳的风险:一项多中心回顾性研究
Infect Drug Resist. 2024 Nov 29;17:5287-5298. doi: 10.2147/IDR.S491910. eCollection 2024.
4
Factors associated with mortality among laboratory-diagnosed drug-resistant tuberculosis patients on treatment, KwaZulu-Natal Province, 2017-2019.2017-2019 年,夸祖鲁-纳塔尔省实验室诊断耐多药结核病患者治疗期间死亡相关因素。
Pan Afr Med J. 2024 Apr 11;47:181. doi: 10.11604/pamj.2024.47.181.34571. eCollection 2024.
5
Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia.体重变化对埃塞俄比亚西北部耐多药结核病患者治疗结局的影响。
Sci Rep. 2024 Jan 4;14(1):508. doi: 10.1038/s41598-023-51026-y.
6
Evaluating determinants of treatment outcomes among tuberculosis patients in the mining district of Butha Buthe, Lesotho.评估莱索托布塔布泰矿区结核病患者治疗结果的决定因素。
IJID Reg. 2023 Mar;6:62-67. doi: 10.1016/j.ijregi.2022.12.008. Epub 2022 Dec 29.
7
Predictors of unfavourable treatment outcome in patients diagnosed with drug-resistant tuberculosis in the Torres Strait / Papua New Guinea border region.在托雷斯海峡/巴布亚新几内亚边境地区诊断为耐药结核病的患者中,不良治疗结果的预测因素。
PLoS One. 2022 Dec 9;17(12):e0266436. doi: 10.1371/journal.pone.0266436. eCollection 2022.
8
Sociodemographic and Clinical Factors Associated with Treatment Outcomes for Drug-resistant Tuberculosis.与耐多药结核病治疗结果相关的社会人口学和临床因素。
Am J Trop Med Hyg. 2022 Oct 31;107(6):1295-1301. doi: 10.4269/ajtmh.22-0294. Print 2022 Dec 14.
9
Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country.在一个高负担国家,个体化较长疗程与标准化较短疗程治疗耐多药结核病的比较效果
Front Pharmacol. 2022 Sep 6;13:973713. doi: 10.3389/fphar.2022.973713. eCollection 2022.
10
Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling.埃塞俄比亚西北部耐多药结核病患者不良治疗结局预测列线图的开发与验证:预测模型的应用
Infect Drug Resist. 2022 Jul 21;15:3887-3904. doi: 10.2147/IDR.S372351. eCollection 2022.

本文引用的文献

1
Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.实施与运营研究:Xpert MTB/RIF检测对耐多药结核病患者的临床影响
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e1-7. doi: 10.1097/QAI.0000000000001110.
2
Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.南非开普敦凯伊利沙地区耐利福平结核病患者开始接受抗逆转录病毒治疗的时间:对死亡率和治疗成功率的影响
PLoS One. 2015 Nov 10;10(11):e0142873. doi: 10.1371/journal.pone.0142873. eCollection 2015.
3
Management of multi- and extensively drug-resistant tuberculosis in Ukraine: how well are we doing?乌克兰耐多药和广泛耐药结核病的管理:我们做得如何?
Public Health Action. 2014 Oct 21;4(Suppl 2):S67-72. doi: 10.5588/pha.14.0035.
4
Pattern of primary tuberculosis drug resistance and associated treatment outcomes in Transnistria, Moldova.摩尔多瓦德涅斯特河沿岸地区原发性肺结核耐药模式及相关治疗结果
Public Health Action. 2014 Oct 21;4(Suppl 2):S64-6. doi: 10.5588/pha.14.0043.
5
Do incentives improve tuberculosis treatment outcomes in the Republic of Moldova?激励措施能否改善摩尔多瓦共和国的结核病治疗效果?
Public Health Action. 2014 Oct 21;4(Suppl 2):S59-63. doi: 10.5588/pha.14.0047.
6
Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes.拉脱维亚的多重耐药和广泛耐药结核病:趋势、特征及治疗结果
Public Health Action. 2014 Oct 21;4(Suppl 2):S47-53. doi: 10.5588/pha.14.0041.
7
Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus.白俄罗斯共和国戈梅利地区耐多药结核病患者的治疗效果不佳。
Public Health Action. 2014 Oct 21;4(Suppl 2):S24-8. doi: 10.5588/pha.14.0042.
8
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.改善耐多药结核病的治疗效果:积极的治疗方案可预防治疗失败和死亡。
Clin Infect Dis. 2014 Jul 1;59(1):9-15. doi: 10.1093/cid/ciu209. Epub 2014 Apr 11.
9
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.强化方案治疗耐多药结核病可降低全因死亡率。
PLoS One. 2013;8(3):e58664. doi: 10.1371/journal.pone.0058664. Epub 2013 Mar 13.
10
Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.强化方案治疗耐多药结核病可降低复发率。
Clin Infect Dis. 2013 Mar;56(6):770-6. doi: 10.1093/cid/cis1008. Epub 2012 Dec 7.

乌克兰基辅州耐多药结核病治疗效果不佳的风险因素。

Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.

作者信息

Aibana Omowunmi, Bachmaha Mariya, Krasiuk Viatcheslav, Rybak Natasha, Flanigan Timothy P, Petrenko Vasyl, Murray Megan B

机构信息

Division of General Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.

Brown University School of Public Health, Providence, RI, USA.

出版信息

BMC Infect Dis. 2017 Feb 7;17(1):129. doi: 10.1186/s12879-017-2230-2.

DOI:10.1186/s12879-017-2230-2
PMID:28173763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5294867/
Abstract

BACKGROUND

Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcomes in Ukraine.

METHODS

We conducted a retrospective analysis of patients initiated on MDR-TB treatment in the Kyiv Oblast of Ukraine between January 01, 2012 and March 31st, 2015. We defined good treatment outcomes as cure or completion and categorized poor outcomes among those who died, failed treatment or defaulted. We used logistic regression analyses to identify baseline patient characteristics associated with poor MDR-TB treatment outcomes.

RESULTS

Among 360 patients, 65 (18.1%) achieved treatment cure or completion while 131 (36.4%) died, 115 (31.9%) defaulted, and 37 (10.3%) failed treatment. In the multivariate analysis, the strongest baseline predictors of poor outcomes were HIV infection without anti-retroviral therapy (ART) initiation (aOR 10.07; 95% CI 1.20-84.45; p 0.03) and presence of extensively-drug resistant TB (aOR 9.19; 95% CI 1.17-72.06; p 0.03). HIV-positive patients initiated on ART were not at increased risk of poor outcomes (aOR 1.43; 95% CI 0.58-3.54; p 0.44). There was no statistically significant difference in risk of poor outcomes among patients who received baseline molecular testing with Gene Xpert compared to those who were not tested (aOR 1.31; 95% CI 0.63-2.73).

CONCLUSIONS

Rigorous compliance with national guidelines recommending prompt initiation of ART among HIV/TB co-infected patients and use of drug susceptibility testing results to construct treatment regimens can have a major impact on improving MDR-TB treatment outcomes in Ukraine.

摘要

背景

乌克兰是全球耐多药结核病(MDR-TB)负担最高的十个国家之一。据世界卫生组织报告,乌克兰耐多药结核病的治疗成功率仍低于全球成功率。很少有研究评估乌克兰耐多药结核病治疗效果不佳的预测因素。

方法

我们对2012年1月1日至2015年3月31日期间在乌克兰基辅州开始接受耐多药结核病治疗的患者进行了回顾性分析。我们将良好的治疗结果定义为治愈或完成治疗,并将死亡、治疗失败或违约患者的结果归类为不佳。我们使用逻辑回归分析来确定与耐多药结核病治疗效果不佳相关的基线患者特征。

结果

在360名患者中,65名(18.1%)实现了治疗治愈或完成,而131名(36.4%)死亡,115名(31.9%)违约,37名(10.3%)治疗失败。在多变量分析中,治疗效果不佳的最强基线预测因素是未开始抗逆转录病毒治疗(ART)的艾滋病毒感染(调整后比值比[aOR]为10.07;95%置信区间[CI]为1.20-84.45;P=0.03)和广泛耐药结核病的存在(aOR为9.19;95%CI为1.17-72.06;P=0.03)。开始接受ART治疗的艾滋病毒阳性患者治疗效果不佳的风险并未增加(aOR为1.43;95%CI为0.58-3.54;P=0.44)。与未接受检测的患者相比,接受基于Gene Xpert的基线分子检测的患者治疗效果不佳的风险没有统计学上的显著差异(aOR为1.31;95%CI为0.63-2.73)。

结论

严格遵守国家指南中关于艾滋病毒/结核病合并感染患者及时开始ART治疗以及使用药敏试验结果制定治疗方案的建议,可能会对改善乌克兰耐多药结核病的治疗效果产生重大影响。